Waterfall plot of maximal percentage of IgM reductions and corresponding best overall response. Patients included are those who received ≥1 dose of zanubrutinib, had no prior BTK inhibitor exposure, and had baseline IgM or M-paraprotein ≥5 g/L. Only patients with data at both baseline and any postbaseline visits are included. If the nephelometric IgM test result was missing at baseline, the M-paraprotein result by SPEP was used throughout and summarized together with nephelometric IgM test results for this endpoint.